ImmuCell Corporation
ImmuCell Corp. develops and sells animal health products focused on providing immediate immunity to newborn dairy and beef cattle. The company is best known for its First Defense product line, which is sold primarily through distributors into U.S. dairy and beef markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueColostrum-based products sold to help newborn calves gain immediate immunity.
A newer product line that requires manufacturing, launch, and capacity investment support.
Products
Reported · share of revenue- First Defense Product Line99.3 %
- Other Animal Health0.7 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
ImmuCell sells mainly to distributors serving the U.S. dairy and beef industries, rather than directly to end farmers. The company’s products are used by producers who want to improve calf health and reduce early-life mortality and disease risk, which supports repeat purchasing through animal health channels.
Buys First Defense products to support immediate immunity in newborn calves and reduce early health risk.
Buys the same core products for calf health and early-life disease prevention.
Purchase in bulk and resell into dairy and beef channels; they are critical to market access.
Smaller but growing buyers outside the U.S. that contributed a rising share of sales in 2025.
Strategy
ImmuCell is focused on expanding production capacity for First Defense while conserving cash and limiting large capital spending. Management is also working to improve gross margin and support the launch and scaling of newer products such as Re-Tain.
Demand growth and product concentration make capacity a key constraint on revenue growth.
Manufacturing yield, contamination, and input-cost volatility directly affect profitability and cash generation.
The company has limited scale, so cash conservation supports operating flexibility and product development.
Geography
The business is centered in the United States, where most sales are made into dairy and beef markets. International sales are smaller but have been growing, with management noting a higher share of sales outside the U.S. in 2025. Geography matters mainly because the company’s customer base, distributor network, and demand exposure are concentrated in U.S. livestock markets.
Risks
ImmuCell is highly exposed to concentration risk because nearly all product sales come from First Defense and most sales are tied to two livestock markets and a small number of distributors. The business also faces manufacturing, regulatory, and cybersecurity risks that can disrupt production, compress margins, or impair customer confidence.
- Product concentration in First DefenseImpact: CriticalLikelihood: High
About 99% of product sales come from one product line, so any demand, quality, or competitive issue would have an outsized effect.
Exposure: First Defense product line
- Market concentration in dairy and beefImpact: HighLikelihood: High
Demand depends on livestock industry conditions, herd economics, and producer spending patterns.
Exposure: U.S. dairy and beef industries
- Manufacturing yield and contamination riskImpact: HighLikelihood: High
Biological yield variability and contamination events can raise cost of goods sold and reduce gross margin.
Exposure: Production and inventory
- Customer concentrationImpact: HighLikelihood: Medium
A large portion of sales and receivables is tied to two distributors, increasing counterparty and bargaining-power risk.
Exposure: Two large distributors
- Cybersecurity and IT disruptionImpact: MediumLikelihood: Medium
Operational downtime or data loss could interrupt production, delay shipments, and create legal or reputational damage.
Exposure: Information systems and connected business processes
Accounting
Judgemental itemsTiming depends on delivery terms and collectability assessment, affecting quarterly revenue cut-off.
Impact: Can shift revenue between periods if shipment timing changes
Cost per dose varies with yield, making inventory and gross margin estimates sensitive to production outcomes.
Impact: Affects cost of goods sold, inventory carrying value, and margin
Recoverability depends on future taxable income, which is uncertain for a small, product-concentrated company.
Impact: Can affect tax expense and balance-sheet asset values
Capitalized development or related assets may need impairment if commercialization or profitability lags expectations.
Impact: Could create non-cash write-downs
Similar listed companies
Publicly listed companies with a comparable business focus.
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Imunon, Inc.
IMNN · Pharmaceutical Preparations
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Immunic, Inc
IMUX · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026